MARKET

GLPG

GLPG

Galapagos Nv
NASDAQ
27.27
-0.38
-1.37%
After Hours: 27.91 +0.64 +2.35% 19:56 05/24 EDT
OPEN
27.43
PREV CLOSE
27.65
HIGH
27.46
LOW
27.21
VOLUME
95.71K
TURNOVER
0
52 WEEK HIGH
45.21
52 WEEK LOW
27.21
MARKET CAP
1.80B
P/E (TTM)
13.76
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at GLPG last week (0520-0524)?
Weekly Report · 12h ago
Weekly Report: what happened at GLPG last week (0513-0517)?
Weekly Report · 05/20 09:25
GALAPAGOS <GLPG.AS>: BARCLAYS CUTS TARGET PRICE TO EUR 30 FROM EUR 33
Reuters · 05/20 06:28
Galapagos NV Unveils Employee Subscription Plans
TipRanks · 05/16 21:30
Galapagos NV Expands U.S. CAR-T Therapy Production
TipRanks · 05/16 13:29
BUZZ-Galapagos jumps on collaboration with Blood Centers of America
Shares in Galapagos rise about 3% after announcement of collaboration with Blood Centers of America. Belgium-based drugmaker has access to 50 sites for decentralised manufacturing of CAR-T cell therapies. Stock is top performer on BEL 20 index .BFX. Galapagagos to collaborate with BCA's to manufacture CAR-Ts.
Reuters · 05/16 07:48
GALAPAGOS: KBC SECURITIES RAISES TO BUY FROM ACCUMULATE; TARGET PRICE EUR 50
Reuters · 05/16 07:27
GALAPAGOS NV SHARES UP 4.8% AFTER ANNOUNCING STRATEGIC COLLABORATION WITH BLOOD CENTERS OF AMERICA
Reuters · 05/16 07:05
More
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. It discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

Webull offers Galapagos NV - ADR stock information, including NASDAQ: GLPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLPG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GLPG stock methods without spending real money on the virtual paper trading platform.